Breakthroughs have subsequently been made in clinical cancer immunotherapy by targeting checkpoints CTLA-4, and especially programmed cell death protein 1 (PD-1), which has resulted in United States Food and Drug Administration (FDA) approval for anti-CTLA-4 and anti-PD-1 therapies. Here, PDCD1 is linked to cancer.